Cave rescue

Median Technologies to Participate in the 2024 ASCO Annual Meeting, May 31 - June 4, 2024, McCormick Place, Chicago, IL, USA

Retrieved on: 
onsdag, maj 29, 2024
Technology, Medical Devices, Hospitals, Software, Biotechnology, Radiology, Pharmaceutical, Health, Oncology, Artificial Intelligence, Patient, Progression-free survival, Central review, FDA, PFS, Bias, RECIST, ASCO, Lung cancer, Society, Cave rescue, Annual general meeting

Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”) announced today that the Company will be participating in the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 31 to June 4, McCormick Place, Chicago, IL, USA.

Key Points: 
  • Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”) announced today that the Company will be participating in the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 31 to June 4, McCormick Place, Chicago, IL, USA.
  • The study focused on Discrepancy Rate (DR), bias, endorsement rate, and the impact of adjudication on Progression-Free Survival (PFS) estimates.
  • Results showed significant bias among readers, affecting double readings but no correlation between bias and DR. Additionally, adjudication significantly affects PFS estimates.
  • The ASCO Annual Meeting is the world’s premier oncology conference, organized by the American Society of Clinical Oncology, the largest oncology society in the world.

Median Technologies, a World Leading Oncology Clinical Trial Imaging Services Provider, Becomes Preferred Vendor to Another Top 3 Pharmaceutical Company

Retrieved on: 
tisdag, maj 21, 2024
Medical Devices, Medical Supplies, Hospitals, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, Oncology, CCO, Investment, AI, Cave rescue, MSA, Acceleration

Median Technologies is now preferred provider for two of the Top 3 pharma companies, based on oncology sales2.

Key Points: 
  • Median Technologies is now preferred provider for two of the Top 3 pharma companies, based on oncology sales2.
  • Median will manage central image reads for late phase clinical trials in the client’s oncology pipeline.
  • Fredrik Brag, CEO and Founder of Median Technologies said: “Median’s’ iCRO services are best-in-class and recognized as such worldwide.
  • We are proud to support the pharma industry in bringing the next generation of life-saving oncology drugs to market”.

Median Technologies Reports Full-year 2023 Financial Results and Provides First Quarter 2024 Financial Information

Retrieved on: 
torsdag, april 25, 2024
Biometrics, Radiology, Biotechnology, Oncology, Health, Medical Devices, Health Technology, Clinical Trials, Contract research organization, European Investment Bank, FDA, EIB, United, Stand-alone, Traction, Partnership, BofA Securities, Cave rescue, Artificial intelligence, Growth, ChromeOS, MRMC, LCS, CSF, Bank statement, AUC, Cancer, CE

Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”) today reported its 2023 consolidated annual financial results, as of December 31, 2023, and provided financial information (unaudited) for the first quarter of 2024, as of March 31, 2024.

Key Points: 
  • Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”) today reported its 2023 consolidated annual financial results, as of December 31, 2023, and provided financial information (unaudited) for the first quarter of 2024, as of March 31, 2024.
  • The consolidated financial statements for the financial year ended December 31, 2023, were audited and approved by the Company’s Board of Directors on April 24, 2024.
  • In Quarter 1, our revenues were impacted by the postponement to Quarter 2 of some studies due to late patient recruitment.
  • Consistent with the long-lasting partnership between CSF and Median, this agreement strengthens the future relationship between CSF and Median.

Median Technologies Reports 2023 Revenue and Summarizes 2024 Strategic Outlook

Retrieved on: 
måndag, januari 29, 2024
Biometrics, Radiology, Biotechnology, Oncology, Health, Medical Devices, Health Technology, Clinical Trials, Mortality, ChromeOS, Bank statement, Lung cancer screening, HCC, Patient, Machine learning, Imaging, Artificial intelligence, REALITY, Partnership, Cave rescue, COVID-19, MRMC, Stand-alone, ESMO, AI, Lung cancer, Big Pharma, Growth, LCS, Hepatocellular carcinoma, Medical device, AUC, Acceleration, EIB, Small Business Saturday, Hospital, FDA, BofA Securities, Diagnosis, CE, European Investment Bank, Fine chemical

Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces its 2023 revenue, outlining both its strategic outlook and key milestones for 2024.

Key Points: 
  • Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces its 2023 revenue, outlining both its strategic outlook and key milestones for 2024.
  • Fredrik Brag, Chief Executive Officer and Founder of Median Technologies, commented: "In Q4 2023, our iCRO1 business achieved record-high order intake, which increased significantly our backlog.
  • We expect to return to growth in 2024 on the back of a decline in 2023 revenue due to soft order intake in China caused by the Covid lockdowns in 2022 and H1 2023."
  • The Standalone study will be finalized in Q2 2024 and the MRMC study in Q3 2024.

Median Technologies to Speak at the Radiological Society of North America 2023 Annual Meeting, Nov. 26 - 30, Chicago, IL, USA

Retrieved on: 
onsdag, november 22, 2023
Software, Radiology, Biotechnology, Oncology, Health, Artificial Intelligence, Medical Devices, Technology, RSNA, AI, Cave rescue, Exhibition

Median Technologies (ALMDT) announced today that the Company will be speaking and presenting at the world’s largest medical imaging conference, the Radiological Society of North America (RSNA) 2023 Annual Meeting and Scientific Assembly, being held in Chicago, IL, USA, Nov. 26-30, 2023.

Key Points: 
  • Median Technologies (ALMDT) announced today that the Company will be speaking and presenting at the world’s largest medical imaging conference, the Radiological Society of North America (RSNA) 2023 Annual Meeting and Scientific Assembly, being held in Chicago, IL, USA, Nov. 26-30, 2023.
  • The Company will give a presentation.
  • Details of the session include:
    Median’s iBiopsy® and iCRO teams will be available at booth #4465, Level 3 South Hall (AI showcase) for the duration of the industry exhibition (Nov 26- 29, 10:00 am – 5:00 pm CT).

Median Technologies Reports 2023 Half-year Results and Business Indicators for the Third Quarter of 2023

Retrieved on: 
torsdag, oktober 19, 2023
Biotechnology, Technology, Health, Radiology, Oncology, Medical Devices, Research, Artificial Intelligence, Surgery, Science, Clinical Trials, Survival, FDA, LP, NMPA, Medical device, Q2, Lung cancer, Medicine, Mortality, US Foods, Chinese, Software, Euronext Growth, Q3, Business, Cave rescue, Survival rate, Patient, EIB, Diagnosis, LCS, Rare-earth element, Cryptocurrency, Pharmaceutical industry, Median

Median Technologies (Euronext Growth – ALMDT:PA) (Paris:ALMDT), whose board of Directors approved the consolidated IFRS financial statements for the first half of 2023 on October 18, 2023, today announces its half-year results as well as business indicators for Q3 2023 (unaudited).

Key Points: 
  • Median Technologies (Euronext Growth – ALMDT:PA) (Paris:ALMDT), whose board of Directors approved the consolidated IFRS financial statements for the first half of 2023 on October 18, 2023, today announces its half-year results as well as business indicators for Q3 2023 (unaudited).
  • Commenting on the results, Fredrik Brag, CEO, and co-founder of Median Technologies, said:
    “During the first three quarters of 2023, we made significant strides regarding iBiopsy®.
  • These are key milestones in our roadmap to obtain marketing authorizations for our Software as Medical Device for the US and European markets.
  • Median is poised to play a pivotal role to help significantly reduce the lung cancer mortality rate through more effective diagnosis of early-stage patients.

Median Technologies’ Global iCRO Team to participate in the 2023 ESMO Congress, Oct 20 – 24, 2023, Madrid, Spain

Retrieved on: 
måndag, oktober 16, 2023
Oncology, Medical Devices, Health, Health Technology, Pharmaceutical, Biotechnology, Congress, European Society for Medical Oncology, ESMO, Cave rescue, Nightclub

Median Technologies (ALMDT:PA) announced today that the Company will be participating in the prestigious 2023 European Society for Medical Oncology (ESMO) Congress, set to take place in Madrid, Spain (venue: IFEMA).

Key Points: 
  • Median Technologies (ALMDT:PA) announced today that the Company will be participating in the prestigious 2023 European Society for Medical Oncology (ESMO) Congress, set to take place in Madrid, Spain (venue: IFEMA).
  • The event, scheduled from October 20th to 24th, promises to be a remarkable platform for the exchange of groundbreaking insights and cutting-edge developments in the field of oncology.
  • “As a testament to the commitment of advancing cancer care worldwide, we will be participating with the goal of sharing our expertise in clinical trial imaging as well as advanced, AI-powered insights,” said Nicolas Dano, Chief Operating Officer, iCRO, of Median Technologies.
  • “We are thrilled to be bringing together for the first time our expert teams spanning across the Europe, United States, and China, and invite all attendees to visit booth #552 to engage with our experts and experience firsthand the impact of our pioneering solutions.”
    More about the ESMO congress: https://www.esmo.org/meeting-calendar/esmo-congress-2023

Imaging Endpoints Appoints Manish Sharma, MD as Chief Scientific Officer

Retrieved on: 
onsdag, september 6, 2023
Metadata, Bureau of Oceans and International Environmental and Scientific Affairs, Cave rescue, Big data, Deep learning, Clinical trial, NDA, Cure, Doctor of Philosophy, Aptitude, Patient, Growth, ANDA, Research, IND, ChromeOS, Data science, Medical imaging, MD

SCOTTSDALE, Ariz., Sept. 6, 2023 /PRNewswire/ -- Imaging Endpoints (IE), the global leader in oncology-trial imaging and among the largest imaging CROs (iCROs) globally, is pleased to announce the appointment of Manish Sharma, MD as its Chief Scientific Officer.

Key Points: 
  • SCOTTSDALE, Ariz., Sept. 6, 2023 /PRNewswire/ -- Imaging Endpoints (IE), the global leader in oncology-trial imaging and among the largest imaging CROs (iCROs) globally, is pleased to announce the appointment of Manish Sharma, MD as its Chief Scientific Officer.
  • Dr Sharma, a radiologist with over 20 years of extensive experience in clinical research, medical imaging, and data science, joins Imaging Endpoints with a proven track record of excellence.
  • "Manish's extensive expertise and innovative approach align perfectly with our vision to 'Connect Imaging to the Cure,'" said Ronald Korn, MD, PhD, Chief Medical Officer and Founder of Imaging Endpoints.
  • Dr. Sharma will oversee Medical and Scientific Affairs as well as Research and Development at Imaging Endpoints.

Imaging Endpoints Appoints Manish Sharma, MD as Chief Scientific Officer

Retrieved on: 
onsdag, september 6, 2023
Metadata, Bureau of Oceans and International Environmental and Scientific Affairs, Cave rescue, Big data, Deep learning, Clinical trial, NDA, Cure, Doctor of Philosophy, Aptitude, Patient, Growth, ANDA, Research, IND, ChromeOS, Data science, Medical imaging, MD

SCOTTSDALE, Ariz., Sept. 6, 2023 /PRNewswire/ -- Imaging Endpoints (IE), the global leader in oncology-trial imaging and among the largest imaging CROs (iCROs) globally, is pleased to announce the appointment of Manish Sharma, MD as its Chief Scientific Officer.

Key Points: 
  • SCOTTSDALE, Ariz., Sept. 6, 2023 /PRNewswire/ -- Imaging Endpoints (IE), the global leader in oncology-trial imaging and among the largest imaging CROs (iCROs) globally, is pleased to announce the appointment of Manish Sharma, MD as its Chief Scientific Officer.
  • Dr Sharma, a radiologist with over 20 years of extensive experience in clinical research, medical imaging, and data science, joins Imaging Endpoints with a proven track record of excellence.
  • "Manish's extensive expertise and innovative approach align perfectly with our vision to 'Connect Imaging to the Cure,'" said Ronald Korn, MD, PhD, Chief Medical Officer and Founder of Imaging Endpoints.
  • Dr. Sharma will oversee Medical and Scientific Affairs as well as Research and Development at Imaging Endpoints.

Median Technologies Reports Its Business Activity for the First Half of 2023 and Announces the First Step of Its Refinancing Plan

Retrieved on: 
onsdag, juli 12, 2023
Data Management, Biotechnology, Technology, Other Health, Health, Biometrics, Oncology, Health Technology, Medical Devices, Software, Artificial Intelligence, Medical device, CE, Euronext Growth, US, EU, Cave rescue, LCS, Bank statement, BofA Securities, Clinical trial, Lung cancer screening, Fruit, Burn, European Investment Bank, Convertible, MRMC, CSF, EIB, FDA, Pharmaceutical industry, LP

Median Technologies (Euronext Growth - ALMDT) reports today its business indicators for the first half of 2023 for the iCRO activity (non-audited figures) and the iBiopsy® activity.

Key Points: 
  • Median Technologies (Euronext Growth - ALMDT) reports today its business indicators for the first half of 2023 for the iCRO activity (non-audited figures) and the iBiopsy® activity.
  • "When it comes to our iBiopsy® LCS CADe/CADx Software as Medical Device, the design of our pivotal validation plan has been finalized since March 2023.
  • In Q2 2023, the Company's revenue stands at €5.8M, up by 3.6% from Q1 2023 and 13.7% compared to Q4 2022 revenue.
  • As at June 30, 2023, Median Technologies' cash and cash equivalents stand at €8.3M, compared to €13.1M at March 31, 2023, i.e.